Navigation Links
Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Date:10/1/2007

BETHESDA, Md., Oct. 2 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) announced today that Anthony P. Deasey, 58, has been appointed as the Company's Senior Vice President of Finance and Chief Financial Officer, and has been elected to the Board of Directors.

Prior to joining NWBT, from November 2000 to September 2007 Mr. Deasey served as Executive Vice President, Chief Financial and Chief Operating Officer of Celsion Corporation, a biotechnology company headquartered in Columbia, Maryland. At Celsion, Mr. Deasey played a key role in transitioning Celsion from a medical device to an oncology drug development company, and acquired substantial experience with oncology regulatory and market factors. In addition to Celsion, Mr. Deasey previously served as Chief Financial Officer of two public companies with domestic and international operations and a diverse range of products with up to $800 million in revenues.

"We are very pleased to announce the appointment of Tony as our Chief Financial Officer," said Alton Boynton, PhD, President and Chief Executive Officer of Northwest Biotherapeutics. "As we are in the process of establishing international operations and accelerating our pivotal studies in the United States, Tony's extensive financial, operational and management experience, and his familiarity with the oncology sector, will be a valuable addition to our team."

ABOUT NORTHWEST BIOTHERAPEUTICS, INC.

Northwest Biotherapeutics, Inc. is a US-based biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, and on a cost-effective basis.

The Company has two lead product candidates:

1. DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of

Glioblastoma multiforme; and

2. DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment

of ho
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Northwestern Mutual, American Family make Computerworlds best IT workplaces
2. Northwestern adds to its Imago microscope
3. Imago microscope leads to Northwestern research advance
4. Northwest Wis. Manufacturing Outreach Center honored by DOC, NIST
5. Speaker announces business members of IT Task Force
6. Doyle announces technology tax credits for Berbee
7. Doyle announces new energy, global warming policies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)..., Nov. 6 ,, 3Q09 C...f Qutenza(TM) E.U. Marketing Authorization to Aste...s in commercial readiness activities Expanded man... Marketing; and Director, Commercial Operations A...and Audit Committee chairman , Upcoming 200...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Personali... to take place on February 22-24, 2010 in Philadel...ence we will highlight key issues in forming partn...r experiences. , Minneapo... Arrowhead’s 2010 Personalized Medicine Par...
(Date:11/5/2009)... Nov. 5 DSM Pharmaceutical Product... alliance with Galenix, Saint Jean D,Illac, France... manufacturing partner for Galenix commercial prod... collaborate on business development opportunities...based on the strength of Galenix in drug product d...
(Date:11/5/2009)... 5 Transgenomic, Inc. (O... results for the quarter ended September 30, 2009....the tables that follow. ,, Third Quarter 2009 ... or $0.01 per share for the third quarter of 2009 ... share for the third quarter of 2008. ,, Net s...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
... /PRNewswire-FirstCall/ - Spectral Diagnostics Inc...its relationship with Toray,Medical Co. Ltd. for t...vity Assay (EAA(TM)), the only FDA cleared assay f...f the new collaboration agreement, Spectral,will h...ic territories,including China, India, Russia and ...
...artners with Bioscene in Japan - Expands Presence ...Xennex) announced,today that the Japan Patent Offi...nounced that it has selected Bioscene Informatics ...istribution of GeneCards in Japan., GeneCards wil...approval,of patent applications in the life scienc...
...N, May 5 /PRNewswire-FirstCall/ - YM BioSciences I... company that identifies,develops and commercializ...today announced that posters describing research c...) will be presented at The 27th Annual,Scientific ...place May,8-10, 2008 in Tampa, Florida., The firs...
Other Biology Technology:Spectral and Toray expand collaboration to include new geographic territories 2Spectral and Toray expand collaboration to include new geographic territories 3Japan Patent Office Licenses GeneCards(R) from Xennex, Inc. 2Japan Patent Office Licenses GeneCards(R) from Xennex, Inc. 3Japan Patent Office Licenses GeneCards(R) from Xennex, Inc. 4YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING 2
(Date:11/4/2009)...n the cities of Long Beach and Riverside are respo... childhood asthma, and the true impact of air poll... been underestimated, according to researchers at ...The study, which appears in an online edition of t...that nine percent of all childhood asthma cases in...
(Date:11/4/2009)...a at Norman has received more than $10 million in ... of the federal stimulus program, bringing thetota...chers to $23 million. Thirty-three projects achie...aeology to weather. , "The university has though...g areasof scholarly excellence to federal agency p...
(Date:11/4/2009)...20 Aware, Inc. (Nasdaq: ...y and biometrics software, today reported financia...0, 2009. ,, Michael Tzannes, Aware,s Chairman..., we announced an agreement to sell our DSL and ho...ss semiconductor company being spun out of Infineo...
Breaking Biology News(10 mins):USC study finds big air pollution impacts on local communities 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 1Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 2Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 3Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 4Brain Scans Could Help Spot Schizophrenia Earlier 56674 1Brain Scans Could Help Spot Schizophrenia Earlier 56674 2Leading Expert Available to Weigh in on Health Care Reform 56672 1Leading Expert Available to Weigh in on Health Care Reform 56672 2Leading Expert Available to Weigh in on Health Care Reform 56672 3
...arbara, Calif.) - It took a decade of painstaking ..., and a database of more than 200,000 fossil recor...he conventional wisdom about the diversity of mari...rcher with the National Center for Ecological Anal... the principal author of a report published in the...
...AA coral bleaching prediction system indicates tha...ter this year, but the event will probably not be ...bleaching outlook this week at the 11th Internatio... The system also suggests that there is a risk of... Islands in August, but little bleaching elsewhere...
...kins Ice Shelf is experiencing further disintegrat...idge connecting the shelf to Charcot Island. Since...helps to stabilise the ice shelf, it is likely the...the ice shelf at risk. , This animation, comprise...ic Aperture Radar (ASAR) between 30 May and 9 July...
Other Biology News:UCSB researcher leads worldwide study on marine fossil diversity 2New NOAA coral bleaching prediction system calls for low level of bleaching in Caribbean this year 2Wilkins Ice Shelf hanging by its last thread 2Wilkins Ice Shelf hanging by its last thread 3
... analytical to medium scale affinity purification ...vectors. Sufficient reagents are provided for puri... or denaturing conditions. Crude samples are incub...tains STag fusion proteins. After unbound proteins...
...ines deep experience, skills and flexibility in pr...orative team chemistry. This combination enables o...oval and beyond.,With AAIBiotech, you can cou...ou get more than that: its the power of team chemi...
Mouse Anti-Human S-100 alpha/beta chain Monoclonal Antibody, Unconjugated, Clone 8B10 from Santa Cruz Biotechnology, Inc.
Corning Proculture Spinner Flask,15L,Vertical S/Arm, No. Of S/A 4,Cent Neck 100mm from Sigma-Aldrich
Biology Products: